Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis

Cancer Cell

Volumn 5, Issue 5, 2004, Pages 455-463

  Zhu, Ping ^a,f   Martin, Elke ^b   Mengwasser, Jörg ^b   Schlag, Peter ^c   Janssen, Klaus Peter ^d   Göttlicher, Martin ^a,e  

^a KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^b Karlsruhe Branch   (Germany)

^c Section of Pathology   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE 2; MYC PROTEIN; UNCLASSIFIED DRUG; VALPROIC ACID; WNT PROTEIN;

ADENOMA; ADENOMATOSIS POLYPOSIS COLI GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENESIS; COLON CANCER; COLORECTAL TUMOR; CONTROLLED STUDY; EXPLANT; FEMALE; GENE LOSS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INTESTINE MUCOSA; MALE; MOUSE; NONHUMAN; POLYP; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR SUPPRESSOR GENE;

ANIMALIA;

EID: 2342603414     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(04)00114-X     Document Type: Article

References (49)

1. Barak Y., Liao D., He W., Ong E.S., Nelson M.C., Olefsky J.M., Boland R., Evans R.M. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc. Natl. Acad. Sci. USA. 99:2002;303-308
2. Behrens J., von Kries J.P., Kuhl M., Bruhn L., Wedlich D., Grosschedl R., Birchmeier W. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature. 382:1996;638-642
3. Berger S.L. Histone modifications in transcriptional regulation. Curr. Opin. Genet. Dev. 12:2002;142-148
4. Blaheta R.A., Cinatl J. Jr. Anti-tumor mechanisms of valproate. A novel role for an old drug Med. Res. Rev. 22:2002;492-511
5. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:2001;494-498
6. Fodde R. The multiple functions of tumour suppressors. It's all in APC Nat. Cell Biol. 5:2003;190-192
7. Fodde R., Edelmann W., Yang K., van Leeuwen C., Carlson C., Renault B., Breukel C., Alt E., Lipkin M., Khan P.M., et al. A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc. Natl. Acad. Sci. USA. 91:1994;8969-8973
8. Giles R.H., van Es J.H., Clevers H. Caught up in a Wnt storm. Wnt signaling in cancer Biochim. Biophys. Acta. 1653:2003;1-24
9. Glass C.K., Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 14:2000;121-141
10. Göttlicher M., Minucci S., Zhu P., Krämer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo Coco F., Nervi C., Pelicci P.G., Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20:2001;6969-6978
11. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70
12. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., Morin P.J., Vogelstein B., Kinzler K.W. Identification of c-MYC as a target of the APC pathway. Science. 281:1998;1509-1512
13. He T.C., Chan T.A., Vogelstein B., Kinzler K.W. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell. 99:1999;335-345
14. Hugh T.J., Dillon S.A., O'Dowd G., Getty B., Pignatelli M., Poston G.J., Kinsella A.R. Beta-Catenin expression in primary and metastatic colorectal carcinoma. Int. J. Cancer. 82:1999;504-511
15. Janssen K.P., el-Marjou F., Pinto D., Sastre X., Rouillard D., Fouquet C., Soussi T., Louvard D., Robine S. Targeted expression of oncogenic K-ras in intestinal epithelium causes spontaneous tumorigenesis in mice. Gastroenterology. 123:2002;492-504
16. Jenuwein T., Allis C.D. Translating the histone code. Science. 293:2001;1074-1080
17. Johnstone R.W. Histone-deacetylase inhibitors. Novel drugs for the treatment of cancer Nat. Rev. Drug Discov. 1:2002;287-299
18. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 87:1996;159-170
19. Korinek V., Barker N., Morin P.J., van Wichen D., de Weger R., Kinzler K.W., Vogelstein B., Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science. 275:1997;1784-1787
20. Krämer O.H., Göttlicher M., Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab. 12:2001;294-300
21. Krämer O.H., Zhu P., Ostendorff H.P., Golebiewski M., Tiefenbach J., Peters M.A., Brill B., Groner B., Bach I., Heinzel T., Göttlicher M. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 22:2003;3411-3420
22. Lagger G., O'Carroll D., Rembold M., Khier H., Tischler J., Weitzer G., Schuettengruber B., Hauser C., Brunmeir R., Jenuwein T., Seiser C. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 21:2002;2672-2681
23. Laird P.W., Jackson-Grusby L., Fazeli A., Dickinson S.L., Jung W.E., Li E., Weinberg R.A., Jaenisch R. Suppression of intestinal neoplasia by DNA hypomethylation. Cell. 81:1995;197-205
24. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone deacetylases and cancer. Causes and therapies Nat. Rev. Cancer. 1:2001;194-202
25. Melnick A., Licht J.D. Histone deacetylases as therapeutic targets in hematologic malignancies. Curr. Opin. Hematol. 9:2002;322-332
26. Molenaar M., van de Wetering M., Oosterwegel M., Peterson-Maduro J., Godsave S., Korinek V., Roose J., Destree O., Clevers H. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell. 86:1996;391-399
27. Monteiro A.N. BRCA1. Exploring the links to transcription Trends Biochem. Sci. 25:2000;469-474
28. Morin P.J. Beta-Catenin signaling and cancer. Bioessays. 21:1999;1021-1030
29. Morin P.J., Vogelstein B., Kinzler K.W. Apoptosis and APC in colorectal tumorigenesis. Proc. Natl. Acad. Sci. USA. 93:1996;7950-7954
30. Park B.H., Vogelstein B., Kinzler K.W. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. Proc. Natl. Acad. Sci. USA. 98:2001;2598-2603
31. Phiel C.J., Klein P.S. Molecular targets of lithium action. Annu. Rev. Pharmacol. Toxicol. 41:2001;789-813
32. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276:2001;36734-36741
33. Remiszewski S.W. Recent advances in the discovery of small molecule histone deacetylase inhibitors. Curr. Opin. Drug Discov. Dev. 5:2002;487-499
34. Scully R. Interactions between BRCA proteins and DNA structure. Exp. Cell Res. 264:2001;67-73
35. Sears R., Leone G., DeGregori J., Nevins J.R. Ras enhances Myc protein stability. Mol. Cell. 3:1999;169-179
36. Shoemaker A.R., Gould K.A., Luongo C., Moser A.R., Dove W.F. Studies of neoplasia in the Min mouse. Biochim. Biophys. Acta. 1332:1997;F25-F48
37. Shtutman M., Zhurinsky J., Simcha I., Albanese C., D'Amico M., Pestell R., Ben-Ze'ev A. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA. 96:1999;5522-5527
38. Stambolic V., Ruel L., Woodgett J.R. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr. Biol. 6:1996;1664-1668
39. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature. 403:2000;41-45
40. Su L.K., Kinzler K.W., Vogelstein B., Preisinger A.C., Moser A.R., Luongo C., Gould K.A., Dove W.F. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science. 256:1992;668-670
41. Tetsu O., McCormick F. beta-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature. 398:1999;422-426
42. Valizadeh A., Karayiannakis A.J., el-Hariry I., Kmiot W., Pignatelli M. Expression of E-cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120) in colorectal polyps. Am. J. Pathol. 150:1997;1977-1984
43. van de Wetering M., Sancho E., Verweij C., de Lau W., Oving I., Hurlstone A., van der Horn K., Batlle E., Coudreuse D., Haramis A.P., et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 111:2002;241-250
44. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., Ghosh D., Pienta K.J., Sewalt R.G., Otte A.P., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 419:2002;624-629
45. Verdin E., Dequiedt F., Kasler H.G. Class II histone deacetylases. Versatile regulators Trends Genet. 19:2003;286-293
46. Yang W.M., Inouye C., Zeng Y., Bearss D., Seto E. Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3. Proc. Natl. Acad. Sci. USA. 93:1996;12845-12850
47. Yang W.M., Yao Y.L., Sun J.M., Davie J.R., Seto E. Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family. J. Biol. Chem. 272:1997;28001-28007
48. Zeng Y., Tang C.M., Yao Y.L., Yang W.M., Seto E. Cloning and characterization of the mouse histone deacetylase-2 gene. J. Biol. Chem. 273:1998;28921-28930
49. Zhang C.L., McKinsey T.A., Chang S., Antos C.L., Hill J.A., Olson E.N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 110:2002;479-488